Ignite Creation Date:
2024-05-06 @ 6:40 PM
Last Modification Date:
2024-10-26 @ 2:52 PM
Study NCT ID:
NCT05747729
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-02-28
First Post:
2023-02-18
Brief Title:
A Single-arm Open-label Clinical Trial of SurufatinibSerplulimabPlatinumEtoposide in Neuroendocrine Carcinoma
Sponsor:
Wuhan Union Hospital China
Organization:
Wuhan Union Hospital China
Study Overview
Official Title:
A Single-arm Open-label Single-center Clinical Trial of Surufatinib and Serplulimab Combined With Standard Chemotherapy PlatinumEtoposide in Neuroendocrine Carcinoma
Status:
NOT_YET_RECRUITING
Status Verified Date:
2023-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a prospective open-label single-arm single-center clinical study Patients with neuroendocrine carcinoma who had not previously received standard therapy were enrolled in this study once they have signed the informed consent form ICF and been identified as eligible in screening This clinical trial evaluates the efficacy and safety of surufatinib and serplulimab combined with standard chemotherapy PlatinumEtoposide in neuroendocrine carcinoma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None